SGLT2 inhibitor trials have helped to shine a stronger spotlight on heart failure risks in type 2 diabetes at a time when such risks have matched – and even exceeded – those for acute myocardial infarction or strokes as first vascular events in diabetes patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.